Craig Peterson, MD
Urology · Montrose, CONPI 1598739054
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.8%), food and beverage and other — rather than concentrated in one kind of arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.6%. Reporting peaked in 2022 at $6,273 and has fallen 74.1% since, to $1,627 in 2025.
Across 139 payments — averaging $112.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$3K
- Neotract Inc.$2K
- Coloplast$2K
- Boston Scientific$2K
- Teleflex LLC$2K
- Valencia Technologies Corporation$1K
- plus $3K from 21 others
What the payments were for
- Travel & lodging$8,40754%
- Food & beverage$6,08239%
- Education$680%
- Other$1,0627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 18 | $3,370 |
| Neotract Inc. | 20 | $2,342 |
| Coloplast | 19 | $1,996 |
| Boston Scientific | 19 | $1,989 |
| Teleflex LLC | 15 | $1,595 |
| Valencia Technologies Corporation | 7 | $1,448 |
| Olympus America Inc. | 2 | $1,078 |
| Olympus Corporation Of The Americas | 5 | $1,066 |
| Myriad Genetic Laboratories, Inc. | 3 | $163 |
| Astellas Pharma US Inc | 8 | $154 |
| 180 Medical, Inc. | 2 | $48 |
| Ferring Pharmaceuticals Inc. | 3 | $46 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $39 |
| Axonics, Inc. | 2 | $36 |
| Convatec Inc. | 2 | $29 |
| AbbVie | 1 | $24 |
| Photocure Inc | 1 | $24 |
| Angiodynamics, Inc. | 1 | $21 |
| Intuitive Surgical | 1 | $20 |
| Urogen Pharma, Inc. | 1 | $18 |
| Telix Pharmaceuticals | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Blue Earth Diagnostics | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$3,148
- UroLift$2,739
- eCoin Device Kit$1,209
- EVIS EXERA lll COLONOVIDEOSCOPE$1,062
- TITAN$1,030
- iTIND System$1,026
- ALTIS$536
- FLEXIVA$170
- Prolaris$134
How this compares
$15,620 in reported general payments places this provider in the 85th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 39 | $36,097 |
| NitrofurantoinNitrofurantoin Macrocrystal | 127 | $5,478 |
| Trospium Chloride | 60 | $4,356 |
| Tamsulosin Hcl | 393 | $4,303 |
| Potassium Citrate ErPotassium Citrate | 17 | $2,764 |
| Methenamine Hippurate | 46 | $2,747 |
| Finasteride | 220 | $2,395 |
| Estradiol | 34 | $2,299 |
| Cabergoline | 13 | $868 |
| YuvafemEstradiol | 15 | $832 |
| Desmopressin Acetate | 24 | $700 |
| Testosterone Cypionate | 14 | $616 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 30 | $581 |
| CefuroximeCefuroxime Axetil | 14 | $479 |
| Oxybutynin Chloride ErOxybutynin Chloride | 54 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $154 | $36,09739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 urology providers in Colorado.
Other urology in Montrose
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
- Nicholas WestfallGrand Junction$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.